company background image
0PT logo

Prothena DB:0PT Stock Report

Last Price

€13.20

Market Cap

€726.2m

7D

-9.0%

1Y

-61.8%

Updated

02 Jan, 2025

Data

Company Financials +

Prothena Corporation plc

DB:0PT Stock Report

Market Cap: €726.2m

0PT Stock Overview

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. More details

0PT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 73% below our estimate of its fair value

Revenue is forecast to grow 36.78% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Prothena Corporation plc Competitors

Formycon

XTRA:FYB

€965.8m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€113.3m

Medigene

XTRA:MDG1

€14.9m

Price History & Performance

Summary of share price highs, lows and changes for Prothena
Historical stock prices
Current Share PriceUS$13.20
52 Week HighUS$37.00
52 Week LowUS$9.90
Beta0.062
1 Month Change1.54%
3 Month Change-12.58%
1 Year Change-61.85%
3 Year Change-66.50%
5 Year Change-3.65%
Change since IPO169.39%

Recent News & Updates

Recent updates

Shareholder Returns

0PTDE BiotechsDE Market
7D-9.0%4.0%0.7%
1Y-61.8%-10.2%8.4%

Return vs Industry: 0PT underperformed the German Biotechs industry which returned -11.7% over the past year.

Return vs Market: 0PT underperformed the German Market which returned 8.4% over the past year.

Price Volatility

Is 0PT's price volatile compared to industry and market?
0PT volatility
0PT Average Weekly Movement18.8%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0PT's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0PT's weekly volatility has increased from 12% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012173Gene Kinneywww.prothena.com

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
0PT fundamental statistics
Market cap€726.17m
Earnings (TTM)-€128.46m
Revenue (TTM)€129.94m

5.5x

P/S Ratio

-5.6x

P/E Ratio

Is 0PT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0PT income statement (TTM)
RevenueUS$133.35m
Cost of RevenueUS$234.24m
Gross Profit-US$100.89m
Other ExpensesUS$30.94m
Earnings-US$131.83m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.45
Gross Margin-75.66%
Net Profit Margin-98.86%
Debt/Equity Ratio0%

How did 0PT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 01:26
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prothena Corporation plc is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Tazeen AhmadBofA Global Research
null nullBTIG